Literature DB >> 8053539

Current trends in the management of allergic diseases.

J Bousquet1, H Dhivert, F B Michel.   

Abstract

Treatment strategies for allergic diseases are based on allergen avoidance, pharmacotherapy and immunotherapy. Allergen avoidance should always be attempted, even if it is rarely complete and needs several days or weeks to be effective. Pharmacotherapy is aimed at reducing symptoms arising from allergen triggers and inflammation. In seasonal allergic diseases, a short treatment course is sufficient to reverse nonspecific hyperreactivity and symptoms. In chronic allergic diseases, however, inflammation is of major importance and symptoms are not always readily controlled. Moreover, the treatment should be prolonged as proposed by Guidelines for the Management of Asthma and Rhinitis (1, 2). Effective and well-tolerated drugs are now available and some may be combined for rhinitis or asthma therapy. In rhinitis, first-line therapy is still based on non-sedating antihistamines and topical corticosteroids. Cromoglycate and other drugs may also be used. For asthma, anti-inflammatory therapy is the first-line treatment. In mild sufferers, cromoglycate, nedocromil or low-dose inhaled steroids can be used. For more severe disease, high doses of inhaled corticosteroids are proposed. Bronchodilators are used as 'rescue' medications, though many patients with severe symptoms need regular bronchodilator therapy. Long-acting beta 2-agonists have been introduced recently, but their exact place in the management of asthma is not yet fully established. Immunotherapy was first introduced in 1911 and was based on decades of physicians' experience, rather than on rational thought. Standardized allergens have improved the efficacy of immunotherapy, but the safety of this treatment needs to be improved.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1994        PMID: 8053539     DOI: 10.1111/j.1398-9995.1994.tb04236.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  4 in total

Review 1.  Cetirizine: a review of its use in children with allergic disorders.

Authors:  C M Spencer; S Noble
Journal:  Paediatr Drugs       Date:  1999 Jan-Mar       Impact factor: 3.022

Review 2.  Specific immunotherapy in house dust mite allergy.

Authors:  J Bousquet; A Des Roches; L Paradis; H Dhivert; F B Michel
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

3.  β-Glucan supplementation, allergy symptoms, and quality of life in self-described ragweed allergy sufferers.

Authors:  Shawn M Talbott; Julie A Talbott; Tracy L Talbott; Elaine Dingler
Journal:  Food Sci Nutr       Date:  2014-01-08       Impact factor: 2.863

Review 4.  β-1,3/1,6-Glucans and Immunity: State of the Art and Future Directions.

Authors:  Elena De Marco Castro; Philip C Calder; Helen M Roche
Journal:  Mol Nutr Food Res       Date:  2020-04-27       Impact factor: 5.914

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.